Literature DB >> 31904819

Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa.

Antonio Vena1, Daniele Roberto Giacobbe1, Cristina Mussini2, Annamaria Cattelan3, Matteo Bassetti1.   

Abstract

Entities:  

Year:  2020        PMID： 31904819     DOI： 10.1093/cid/ciaa003

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  8 in total

Review 1.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

Review 2.  The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  Abdullah Tarık Aslan; Murat Akova
Journal:  Antibiotics (Basel)       Date:  2022-02-20

3.  The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections.

Authors:  Aisling R Caffrey; Haley J Appaneal; J Xin Liao; Emily C Piehl; Vrishali Lopes; Ryan J Dillon; Laura A Puzniak; Kerry L LaPlante
Journal:  Antibiotics (Basel)       Date:  2022-05-06

4.  Real-world use of ceftolozane/tazobactam: a systematic literature review.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Antimicrob Resist Infect Control       Date:  2021-04-08       Impact factor: 4.887

Review 5.  Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients.

Authors:  Jean-François Timsit; Paul-Henri Wicky; Etienne de Montmollin
Journal:  Antibiotics (Basel)       Date:  2022-01-24

Review 6.  Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Ashlan J Kunz Coyne; Amer El Ghali; Dana Holger; Nicholas Rebold; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2022-02-12

Review 7.  Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians.

Authors:  Luigi Principe; Tommaso Lupia; Lilia Andriani; Floriana Campanile; Davide Carcione; Silvia Corcione; Francesco Giuseppe De Rosa; Roberto Luzzati; Giacomo Stroffolini; Marina Steyde; Giuliana Decorti; Stefano Di Bella
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-12

8.  Evaluating the clinical effectiveness of new beta-lactam/beta-lactamase inhibitor combination antibiotics: A systematic literature review and meta-analysis.

Authors:  Geneva M Wilson; Margaret A Fitzpatrick; Kyle Walding; Beverly Gonzalez; Marin L Schweizer; Katie J Suda; Charlesnika T Evans
Journal:  Antimicrob Steward Healthc Epidemiol       Date:  2021-11-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.